Anlotinib versus Placebo as Adjuvant Therapy for Localized High-Grade Soft-Tissue Sarcomas: A Phase II, Double-Blinded, Randomized Controlled Trial
Compared with surgery alone, adjuvant anlotinib following surgery reduces the incidence of disease relapse in localized high-grade STS, with acceptable toxicity.
Authors
- Yangbai Sun (ORCID: https://orcid.org/0000-0002-2853-2813)
- Chunmeng Wang (ORCID: https://orcid.org/0000-0001-9440-6287)
- Tomohiro Fujiwara (ORCID: https://orcid.org/0000-0003-4257-9180)
- Jilong Yang (ORCID: https://orcid.org/0000-0001-5162-3740)
- Lin Yu (ORCID: https://orcid.org/0000-0002-6210-1857)
- Yü Xu (ORCID: https://orcid.org/0000-0002-0894-5311)
- Wangjun Yan (ORCID: https://orcid.org/0000-0001-9178-0687)
- Zhichao Liao (ORCID: https://orcid.org/0000-0003-3279-1161)
- Shengjian Zhang (ORCID: https://orcid.org/0000-0002-0225-8828)
- Jianrong Zhang (ORCID: https://orcid.org/0000-0003-4688-5222)
- Ilia N. Buhtoiarov (ORCID: https://orcid.org/0000-0001-5207-4616)
- Biqiang Zheng (ORCID: https://orcid.org/0000-0002-2870-4654)
- Lingge Yang
- Yan Yan (ORCID: https://orcid.org/0009-0000-5849-1955)
- Yong Chen (ORCID: https://orcid.org/0000-0002-7188-4566)
- Zhengwang Sun (ORCID: https://orcid.org/0000-0003-4011-7038)
- X. Hu
Institutions
- Cleveland Clinic (US)
- Shanghai Medical College of Fudan University (CN)
- Okayama University (JP)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Fudan University Shanghai Cancer Center (CN)
- Victorian Comprehensive Cancer Centre (AU)
- Yueyang Second People's Hospital (CN)
- Melbourne Health (AU)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-02-07
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2531
- Citations
- 5
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.59